

BIOCRYST PHARMACEUTICALS INC

Form 8-K

October 26, 2005

---

**SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report: October 26, 2005**

**BioCryst Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or other jurisdiction of incorporation)

**000-23186**  
(Commission File Number)

**62-1413174**  
(IRS Employer Identification #)

**2190 Parkway Lake Drive, Birmingham, Alabama 35244**  
(Address of Principal Executive Office)

**(205) 444-4600**  
(Registrant's telephone number, including area code)

---

**Item 2.02. Results of Operations and Financial Condition:**

On October 26, 2005, the Company issued a news release announcing its financial results for the quarter ended September 30, 2005, which also referenced a conference call to discuss these results and provide an update on the status of the Company's programs. A copy of the news release is furnished as exhibit 99.1 hereto and is incorporated by reference into Item 9.01 of Form 8-K.

**Item 9.01. Financial Statements and Exhibits:**

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release dated October 26, 2005 entitled BioCryst Reports Third Quarter 2005 Financial Results



**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release dated October 26, 2005 entitled BioCryst Reports Third Quarter 2005 Financial Results